SELLAS Life Sciences Group Inc (SLS) concluded trading on Thursday at a closing price of $0.99, with 28.0 million shares of worth about $27.72 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.84% during that period and on January 23, 2025 the price saw a loss of about -13.25%. Currently the company’s common shares owned by public are about 70.38M shares, out of which, 68.75M shares are available for trading.
Stock saw a price change of 1.96% in past 5 days and over the past one month there was a price change of 10.12%. Year-to-date (YTD), SLS shares are showing a performance of -4.91% which increased to 90.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.50 but also hit the highest price of $1.72 during that period. The average intraday trading volume for SELLAS Life Sciences Group Inc shares is 1.29 million. The stock is currently trading -1.92% below its 20-day simple moving average (SMA20), while that difference is down -7.77% for SMA50 and it goes to -19.30% lower than SMA200.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) currently have 70.38M outstanding shares and institutions hold larger chunk of about 7.65% of that.
The stock has a current market capitalization of $69.60M and its 3Y-monthly beta is at 2.38. It has posted earnings per share of -$0.70 in the same period. It has Quick Ratio of 2.26 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SLS, volatility over the week remained 13.43% while standing at 10.10% over the month.
Stock’s fiscal year EPS is expected to rise by 59.95% while it is estimated to increase by 12.42% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on July 21, 2021 offering an Overweight rating for the stock and assigned a target price of $18 to it. On April 02, 2018, H.C. Wainwright Initiated their recommendations, while on March 19, 2018, Maxim Group Upgrade their ratings for the stock with a price target of $13.
